The Oslo Ischaemia Study: cohort profile.

Autor:	Falk RS; Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway rs@ous-hf.no., Mariampillai JE; Department of Cardiology, Oslo University Hospital, Oslo, Norway., Prestgaard EE; Vestfold Hospital Trust, Tonsberg, Norway., Heir T; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Bodegård J; Department of Cardiology, Oslo University Hospital, Oslo, Norway., Robsahm TE; Department of Research, Cancer Registry of Norway, Oslo, Norway., Grundvold I; Department of Cardiology, Akershus University Hospital, Lorenskog, Lørenskog, Norway., Skretteberg PT; Department of Cardiology, Oslo University Hospital, Oslo, Norway., Engeseth K; Department of Cardiology, Akershus University Hospital, Lorenskog, Lørenskog, Norway., Bjornholt JV; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Microbiology, Oslo University Hospital, Oslo, Norway., Stavem K; Department of Pulmonary Medicine, Akershus University Hospital, Lørenskog, Norway.; Institute of Clinical Medicine, University of Oslo, Lørenskog, Norway., Liestøl K; Institute of Informatics, University of Oslo, Oslo, Norway., Sandvik L; Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway., Thaulow E; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Paediatric Cardiology, Oslo University Hospital, Oslo, Norway., Erikssen G; Department of Cardiology, Oslo University Hospital, Oslo, Norway., Kjeldsen SE; Department of Cardiology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Nephrology, Oslo University Hospital, Oslo, Norway., Gjesdal K; Department of Cardiology, Oslo University Hospital, Oslo, Norway., Erikssen JE; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2021 Oct 13; Vol. 11 (10), pp. e049111. Date of Electronic Publication: 2021 Oct 13.
DOI:	10.1136/bmjopen-2021-049111
Abstrakt:	Purpose: The Oslo Ischaemia Study was designed to investigate the prevalence and predictors of silent coronary disease in Norwegian middle-aged men, specifically validating exercise electrocardiography (ECG) findings compared with angiography. The study has been important in investigating long-term predictors of cardiovascular morbidity and mortality, as well as investigating a broad spectrum of epidemiological and public health perspectives. Participants: In 1972-1975, 2014 healthy men, 40-59 years old, were enrolled in the study. Comprehensive clinical examination included an ECG-monitored exercise test at baseline and follow-ups. The cohort has been re-examined four times during 20 years. Linkage to health records and national health registries has ensured complete endpoint registration of morbidity until the end of 2006, and cancer and mortality until the end of 2017. Findings to Date: The early study results provided new evidence, as many participants with a positive exercise ECG, but no chest pain ('silent ischaemia'), did not have significant coronary artery stenosis after all. Still, they were over-represented with coronary disease after years of follow-up. Furthermore, participants with the highest physical fitness had lower risk of cardiovascular disease, and the magnitude of blood pressure responses to moderate exercise was shown to influence the risk of cardiovascular disease and mortality. With time, follow-up data allowed the scope of research to expand into other fields of medicine, with the aim of investigating predictors and the importance of lifestyle and risk factors. Future Plans: Recently, the Oslo Ischaemia Study has been found worthy, as the first scientific study, to be preserved by The National Archives of Norway. All the study material will be digitised, free to use and accessible for all. In 2030, the Oslo Ischaemia Study will be linked to the Norwegian Cause of Death Registry to obtain complete follow-up to death. Thus, a broad spectrum of additional opportunities opens. Competing Interests: Competing interests: JB is an epidemiologist employed by AstraZeneca. SEK has within the past 3 years received ad hoc lecture honoraria from Getz, Intas, Merck KGaA and Sanofi. (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu